Professor of Public Heath, Department of Public Health and Primary Care, Imperial College London & Honorary Consultant Cardiologist, Imperial College NHS Trust

Prof Ray is Immediate Past President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap, National Institute for Health Research (NIHR) Academic research Collaboration (ARC) National Lead for CVD, Director of ICTU-Global which is an academic ARO at Imperial College London and Director of the Imperial Centre for CVD Prevention (ICCP) 2018-2026.
He received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. His research involves lipids, diabetes and population health serving as global lead for trials and registries. He has >200,000 citations, an H Index of 126, an i10-index of 372 and since 2018 has been recognised by Clarivate Analytics as among the top 0.1% of authors in global medicine, including more than 40 publications in NEJM, Lancet and JAMA. In 2023 he was inducted as a Fellow of the Academy of Medical Sciences, which is UK’s highest honour for clinician scientists.

He led the global development of Inclsiran the first siRNA for cholesterol, European Lead for development of Bempedoic acid the first oral lipid lowering therapy in a decade and the PCSK9 monoclonal programme. He leads or has led the only global registry of FH the FH Studies Collaboration (FHSC) and pivotal registries such as Da Vinci, Santorini, Heymans as well as part of the academic steering group of MILOS, INTERASPIRE and EUROASPIRE VI